Khang & Khang LLP (the "Firm") announces that it is investigating claims against InfuSystem Holdings, Inc. ("InfuSystem" or the "Company") (NYSE MKT: INFU) concerning possible violations of federal securities laws. If you purchased shares of InfuSystem and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org. The investigation focuses on whether InfuSystem and certain of its officers and/or directors violated federal securities laws. On November 7, 2016, InfuSystem filed a Form 8-K with the SEC revealing that the Company's audited financial statements for the fiscal year ended December 31, 2015, and the Company's unaudited financial statements for each of the fiscal quarters ended March 31, 2015 through June 30, 2016 should no longer be relied upon due to "an error related to an overstatement of estimated accounts receivable collections which in turn overstated revenues and pre-tax income by a corresponding amount." The Company further stated that its Audit Committee believes that material adjustments must be made to the Financial Statements and the Company should restate the Financial Statements. If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com. This press release may constitute Attorney Advertising in some jurisdictions.